Mesoblast is already up 20% in Austrian trading. This is a giant step forward with a well capitalized company (CELG) to bring Prochymal to market sometime in our lifetime. Potential huge royalties to OSIR which was not a real possibility only because Mesoblast did not have the necessary capital . Now, with CELG as a partner, investor, and collaborator...look out. Suddenly, this is the real deal.
More amazing survival data released for GVHD in children on Mesoblast website. 5-20% of these children die without the Mesoblast/Orisis drug. Survival of the sickest of the sick up to 80% with the drug. How much longer are the regulators around the globe going to drag their feet on approval and reimbursement. Same amazing data reported and replicated for over ten years now. What a disgrace.